<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30600" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tricyclic Antidepressants</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Moraczewski</surname>
            <given-names>Jordan</given-names>
          </name>
          <aff>Medical College of Georgia at Augusta University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Awosika</surname>
            <given-names>Ayoola O.</given-names>
          </name>
          <aff>University of Illinois College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aedma</surname>
            <given-names>Kapil K.</given-names>
          </name>
          <aff>Unity Point</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jordan Moraczewski declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ayoola Awosika declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kapil Aedma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30600.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Tricyclic antidepressants (TCAs) constitute a class of medications used to manage and treat major depressive disorder (MDD).&#x000a0;These medications function by inhibiting the reuptake of neurotransmitters, such as serotonin and norepinephrine, which can modulate mood, attention, and pain in individuals. The U.S. Food and Drug Administration (FDA)&#x000a0;has approved different TCAs for specific indications based on clinical trials and proven evidence of their effectiveness and safety for specific medical conditions. Evidence-based guidelines recommend TCAs as a second-line treatment for MDD following selective serotonin reuptake inhibitors (SSRIs). Although&#x000a0;TCAs demonstrate&#x000a0;equivocal&#x000a0;efficacy&#x000a0;with&#x000a0;SSRIs when&#x000a0;treating MDD, these medications&#x000a0;cause more significant adverse effects&#x000a0;due to their anticholinergic activity and lower&#x000a0;threshold for overdose. Due to these factors, TCAs are typically not considered the first-line treatment for MDD, even though they have been proven highly effective in managing severe or treatment-refractory depression.&#x000a0;This activity highlights&#x000a0;the mechanism of action, indications, contraindications, adverse event profile, monitoring protocols, relevant interactions, off-label uses, and other pivotal facets of TCA therapy to enhance the competence of interprofessional healthcare team members when caring for patients with MDD and related&#x000a0;conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate candidates for TCA therapy based on the severity of MDD and potential treatment resistance.</p></list-item><list-item><p>Differentiate TCAs from other classes of antidepressant medications, understanding their unique mechanisms of action, adverse effect profiles, and indications for use.</p></list-item><list-item><p>Implement evidence-based guidelines when prescribing TCAs, considering the established efficacy and safety parameters for specific indications.</p></list-item><list-item><p>Communicate about the benefits, risks, and potential side effects of TCA therapy with patients, enabling informed decision-making and treatment adherence.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30600&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30600">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30600.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Tricyclic antidepressants (TCAs) constitute a class of medications that were initially introduced to the market in 1959 as a pharmacotherapy&#x000a0;for&#x000a0;major depressive disorder (MDD).<xref ref-type="bibr" rid="article-30600.r1">[1]</xref>&#x000a0;TCAs are now regarded as second-line treatment options alongside selective serotonin reuptake inhibitors (SSRIs). They acquired the name "tricyclic" due to the presence of 3 rings in their chemical structure. These medications function by inhibiting the reuptake of neurotransmitters such as serotonin and norepinephrine, which can modulate mood, attention, and pain in individuals.&#x000a0;</p>
        <p>The first TCA, imipramine, was initially created as an antipsychotic but was later discovered to have potent antidepressant properties. Imipramine's success prompted additional research, leading to the formulation of subsequent TCAs such as amitriptyline, nortriptyline, desipramine, and doxepin.&#x000a0;</p>
        <table-wrap id="article-30600.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1.&#x000a0;FDA Approval Dates for TCAs</title>
          </caption>
          <table style="width: 302.95px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 92px;" rowspan="1" colspan="1">
<bold>Generic Name</bold>
</td>
                <td style="width: 119.95px;" rowspan="1" colspan="1">
<bold>Approval Date</bold>
</td>
              </tr>
              <tr>
                <td style="width: 92px;" rowspan="1" colspan="1">Imipramine</td>
                <td style="width: 119.95px;" rowspan="1" colspan="1">1959</td>
              </tr>
              <tr>
                <td style="width: 92px;" rowspan="1" colspan="1">Trimipramine</td>
                <td style="width: 119.95px;" rowspan="1" colspan="1">1961</td>
              </tr>
              <tr>
                <td style="width: 92px;" rowspan="1" colspan="1">Amitriptyline</td>
                <td style="width: 119.95px;" rowspan="1" colspan="1">1961</td>
              </tr>
              <tr>
                <td style="width: 92px;" rowspan="1" colspan="1">Nortriptyline</td>
                <td style="width: 119.95px;" rowspan="1" colspan="1">1964</td>
              </tr>
              <tr>
                <td style="width: 92px;" rowspan="1" colspan="1">Desipramine</td>
                <td style="width: 119.95px;" rowspan="1" colspan="1">1964</td>
              </tr>
              <tr>
                <td style="width: 92px;" rowspan="1" colspan="1">Protriptyline</td>
                <td style="width: 119.95px;" rowspan="1" colspan="1">1967</td>
              </tr>
              <tr>
                <td style="width: 92px;" rowspan="1" colspan="1">Doxepin</td>
                <td style="width: 119.95px;" rowspan="1" colspan="1">1969</td>
              </tr>
              <tr>
                <td style="width: 92px;" rowspan="1" colspan="1">Amoxapine</td>
                <td style="width: 119.95px;" rowspan="1" colspan="1">1979</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The U.S. Food and Drug Administration (FDA)&#x000a0;has approved different TCAs for specific indications based on clinical trials and proven evidence of their effectiveness and safety for specific medical conditions. The approval of TCAs varies depending on the formulation, encompassing treatment for various conditions.<xref ref-type="bibr" rid="article-30600.r2">[2]</xref> TCAs that have received FDA approval for the treatment of MDD comprise amitriptyline, amoxapine, doxepin, desipramine, nortriptyline, protriptyline, imipramine, and trimipramine.<xref ref-type="bibr" rid="article-30600.r3">[3]</xref><xref ref-type="bibr" rid="article-30600.r4">[4]</xref> Clomipramine holds FDA approval for treating obsessive-compulsive disorder (OCD) in individuals aged 10 and older.<xref ref-type="bibr" rid="article-30600.r5">[5]</xref>&#x000a0;</p>
        <p>Although&#x000a0;TCAs demonstrate equivocal&#x000a0;efficacy with SSRIs&#x000a0;when treating MDD, these medications&#x000a0;cause more significant adverse effects&#x000a0;due to their anticholinergic activity and lower threshold for overdose.<xref ref-type="bibr" rid="article-30600.r6">[6]</xref><xref ref-type="bibr" rid="article-30600.r7">[7]</xref>&#x000a0;Due to these factors, TCAs are typically not considered the first-line treatment for MDD, even though they have been proven highly effective in treating severe or treatment-refractory depression.<xref ref-type="bibr" rid="article-30600.r8">[8]</xref>&#x000a0;</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>The off-label indications of&#x000a0;TCAs include migraine prophylaxis, OCD, insomnia, anxiety, and the management of chronic pain, particularly neuropathic pain conditions such as myofascial pain, diabetic neuropathy, and postherpetic neuralgia.<xref ref-type="bibr" rid="article-30600.r9">[9]</xref><xref ref-type="bibr" rid="article-30600.r10">[10]</xref><xref ref-type="bibr" rid="article-30600.r11">[11]</xref><xref ref-type="bibr" rid="article-30600.r12">[12]</xref><xref ref-type="bibr" rid="article-30600.r13">[13]</xref><xref ref-type="bibr" rid="article-30600.r14">[14]</xref><xref ref-type="bibr" rid="article-30600.r15">[15]</xref>&#x000a0;Doxepin and amitriptyline are the most frequently utilized TCAs used for migraine prophylaxis.<xref ref-type="bibr" rid="article-30600.r16">[16]</xref><xref ref-type="bibr" rid="article-30600.r17">[17]</xref>&#x000a0;</p>
        <p>Following the lack of success with preferred treatments, including&#x000a0;pregabalin, duloxetine, and milnacipran, TCAs are currently utilized as second-line treatment options for fibromyalgia.<xref ref-type="bibr" rid="article-30600.r18">[18]</xref><xref ref-type="bibr" rid="article-30600.r19">[19]</xref>&#x000a0;TCAs can also be used to treat nocturnal enuresis in children when the first-line therapy with desmopressin proves ineffective.<xref ref-type="bibr" rid="article-30600.r20">[20]</xref></p>
        <table-wrap id="article-30600.table1" position="float" orientation="portrait">
          <caption>
            <title>Table 2.&#x000a0;Off-Label Uses of TCAs</title>
          </caption>
          <table style="width: 582.333px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 13px;">
                <td style="width: 302px; height: 13px;" rowspan="1" colspan="1">
<bold>Off-Label Uses</bold>
</td>
                <td style="width: 194.333px; height: 13px;" rowspan="1" colspan="1">
<bold>Drug (TCAs)</bold>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 302px; height: 13px;" rowspan="1" colspan="1">Chronic pain (neuropathic pain and fibromyalgia)</td>
                <td style="width: 194.333px; height: 13px;" rowspan="1" colspan="1">Amitriptyline and nortriptyline</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 302px; height: 26px;" rowspan="1" colspan="1">Generalized anxiety disorder (GAD) and panic disorder</td>
                <td style="width: 194.333px; height: 26px;" rowspan="1" colspan="1">Amitriptyline and imipramine</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 302px; height: 13px;" rowspan="1" colspan="1">Bulimia nervosa</td>
                <td style="width: 194.333px; height: 13px;" rowspan="1" colspan="1">Imipramine and desipramine</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 302px; height: 13px;" rowspan="1" colspan="1">Attention-deficit/hyperactivity disorders&#x000a0;</td>
                <td style="width: 194.333px; height: 13px;" rowspan="1" colspan="1">Desipramine and nortriptyline</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 302px; height: 13px;" rowspan="1" colspan="1">Enuresis</td>
                <td style="width: 194.333px; height: 13px;" rowspan="1" colspan="1">Imipramine</td>
              </tr>
              <tr style="height: 13.5455px;">
                <td style="width: 302px; height: 13.5455px;" rowspan="1" colspan="1">Insomnia</td>
                <td style="width: 194.333px; height: 13.5455px;" rowspan="1" colspan="1">Doxepin and amitriptyline</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-30600.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>TCAs exert their effects by modulating around 5 distinct neurotransmitter pathways. These medications function by inhibiting serotonin and norepinephrine reuptake within the presynaptic terminals, resulting in elevated concentrations of these neurotransmitters within the synaptic cleft.&#x000a0;The increased levels of norepinephrine and serotonin in the synapse can contribute to the antidepressant effect. In addition, the&#x000a0;neurotransmitters act as competitive antagonists on postsynaptic cholinergic (alpha-1 and alpha-2), muscarinic, and histamine receptors (H1).<xref ref-type="bibr" rid="article-30600.r21">[21]</xref><xref ref-type="bibr" rid="article-30600.r22">[22]</xref> The molecular structure of each receptor significantly impacts TCA's affinity for each of these receptors.</p>
        <p>The chemical structure of a TCA comprises a 3-ringed arrangement with an attached secondary or tertiary amine. Desipramine, nortriptyline, and protriptyline are categorized as secondary amines, whereas amitriptyline, clomipramine, doxepin, imipramine, and trimipramine belong to the group of tertiary amines. Tertiary amines typically exhibit&#x000a0;significant&#x000a0;serotonin reuptake inhibition, whereas secondary amines display heightened inhibition of norepinephrine uptake.<xref ref-type="bibr" rid="article-30600.r23">[23]</xref>&#x000a0;</p>
        <p>The varied amine structures and chemical compositions observed in TCA usage contribute to the diverse adverse effects observed. These factors impact the affinity and binding of TCA receptors.<xref ref-type="bibr" rid="article-30600.r24">[24]</xref> The inhibition of norepinephrine and serotonin reuptake is believed to underlie the mechanism of TCA utilization in treating neuropathic pain and headache.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Understanding the pharmacokinetic properties of TCAs is essential for determining appropriate dosing strategies, predicting drug interactions, and enhancing therapeutic outcomes.</p>
        <p>The vital components of TCA pharmacokinetics are outlined below.</p>
        <p>Absorption: TCAs are readily absorbed in the body following oral administration and usually achieve peak plasma concentrations within 2 to 8 hours. Bioavailability ranges from 40% to 50%, depending on the specific TCA. Food consumption can impact the absorption of TCAs, particularly those with greater lipophilicity, such as amitriptyline. Eating food can slow down the absorption rate and cause a delay in the onset of action.</p>
        <p>Distribution: TCAs exhibit moderate-to-high protein binding, primarily to plasma albumin and extravascular tissues, resulting in a substantial apparent volume of distribution of 5 to 30 L/kg. The degree of protein binding varies among different TCAs. Due to their lipophilic characteristics, TCAs distribute widely throughout the body, including the central nervous system. This attribute of TCA contributes to their capacity to influence diverse neurotransmitter systems.</p>
        <p>Metabolism: The majority of TCAs undergo comprehensive hepatic metabolism through cytochrome P450 (CYP) enzymes, primarily CYP2D6 and CYP2C19. The metabolic pathways include demethylation, hydroxylation, and glucuronidation, forming active and inactive metabolites. Genetic polymorphisms within CYP enzymes can significantly impact the metabolism of&#x000a0;TCAs, resulting in divergent drug responses and potential interactions.</p>
        <p>Elimination: TCAs and their metabolites are primarily eliminated via the renal route, with only about 5% excreted unchanged. The elimination half-life of TCAs differs across various compounds, typically ranging from&#x000a0;10&#x000a0;to&#x000a0;50 hours.</p>
      </sec>
      <sec id="article-30600.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>TCAs are available in the form of oral tablets, capsules, and solutions. Although intravenous (IV) administration of certain TCAs, including clomipramine, has been used in clinical trials, IV is not a customary route for TCA administration.<xref ref-type="bibr" rid="article-30600.r25">[25]</xref> Topical creams and transdermal patches have been studied for specific TCAs, such as imipramine and doxepin.&#x000a0;However, oral administration (PO) remains the&#x000a0;standard method of administration for TCAs.<xref ref-type="bibr" rid="article-30600.r26">[26]</xref>&#x000a0;</p>
        <p>
<bold>Strength</bold>
</p>
        <p>The dosages for each TCA drug may differ, but due to their high risk of adverse effects, the initial dose of the medication is kept low and gradually increased depending on the response levels of the patients.<xref ref-type="bibr" rid="article-30600.r27">[27]</xref>&#x000a0;Patients unresponsive to low doses of TCA may&#x000a0;respond to higher doses,&#x000a0;mainly because TCAs have demonstrated increased efficacy at higher dosages compared to high doses of SSRIs.<xref ref-type="bibr" rid="article-30600.r27">[27]</xref>&#x000a0;</p>
        <p>Although blood monitoring of TCA concentrations is feasible, there exists mixed evidence regarding the impact of this monitoring on treatment outcomes.<xref ref-type="bibr" rid="article-30600.r7">[7]</xref>&#x000a0;In general, patients are typically administered an oral dose of a TCA once daily due to the extended half-life and sedative effects characteristic of this drug class.<xref ref-type="bibr" rid="article-30600.r24">[24]</xref></p>
        <table-wrap id="article-30600.table2" position="float" orientation="portrait">
          <caption>
            <title>Table 3. Adult Dosages of TCAs</title>
          </caption>
          <table style="width: 447.591px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 103px;" rowspan="1" colspan="1">
<bold>Drug (TCAs)</bold>
</td>
                <td style="width: 175px;" rowspan="1" colspan="1">
<bold>Starting Dose (mg/d)</bold>
</td>
                <td style="width: 158.591px;" rowspan="1" colspan="1">
<bold>Dose Range (mg/d)</bold>
</td>
              </tr>
              <tr>
                <td style="width: 103px;" rowspan="1" colspan="1">Imipramine</td>
                <td style="width: 175px;" rowspan="1" colspan="1">25-75</td>
                <td style="width: 158.591px;" rowspan="1" colspan="1">150-300</td>
              </tr>
              <tr>
                <td style="width: 103px;" rowspan="1" colspan="1">Trimipramine</td>
                <td style="width: 175px;" rowspan="1" colspan="1">50-70</td>
                <td style="width: 158.591px;" rowspan="1" colspan="1">100-200</td>
              </tr>
              <tr>
                <td style="width: 103px;" rowspan="1" colspan="1">Amitriptyline</td>
                <td style="width: 175px;" rowspan="1" colspan="1">25-75</td>
                <td style="width: 158.591px;" rowspan="1" colspan="1">150-300</td>
              </tr>
              <tr>
                <td style="width: 103px;" rowspan="1" colspan="1">Nortriptyline</td>
                <td style="width: 175px;" rowspan="1" colspan="1">25-50</td>
                <td style="width: 158.591px;" rowspan="1" colspan="1">75-150</td>
              </tr>
              <tr>
                <td style="width: 103px;" rowspan="1" colspan="1">Desipramine</td>
                <td style="width: 175px;" rowspan="1" colspan="1">50-75</td>
                <td style="width: 158.591px;" rowspan="1" colspan="1">100-200</td>
              </tr>
              <tr>
                <td style="width: 103px;" rowspan="1" colspan="1">Protriptyline</td>
                <td style="width: 175px;" rowspan="1" colspan="1">15-30</td>
                <td style="width: 158.591px;" rowspan="1" colspan="1">30-60</td>
              </tr>
              <tr>
                <td style="width: 103px;" rowspan="1" colspan="1">Doxepin</td>
                <td style="width: 175px;" rowspan="1" colspan="1">50-70</td>
                <td style="width: 158.591px;" rowspan="1" colspan="1">75-150</td>
              </tr>
              <tr>
                <td style="width: 103px;" rowspan="1" colspan="1">Clomipramine</td>
                <td style="width: 175px;" rowspan="1" colspan="1">25</td>
                <td style="width: 158.591px;" rowspan="1" colspan="1">100-250</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p>Patients with hepatic impairment: Impaired hepatic function can diminish the clearance and lead to increased accumulation of TCAs, which undergo substantial metabolism in the liver. Patients with compromised hepatic function might necessitate reduced doses and more frequent monitoring of plasma levels and adverse effects associated with TCAs. Nortriptyline and desipramine may be preferred over other TCAs in patients with hepatic impairment due to their lower potential for causing hepatotoxicity.</p>
        <p>Patients with renal impairment: As TCAs and their metabolites are predominantly eliminated through the renal route, renal impairment in patients can significantly affect their pharmacokinetics.&#x000a0;Nortriptyline may be preferred over other TCAs in patients with renal impairment due to its less-active metabolites and reduced anticholinergic effects.</p>
        <p>Pregnancy considerations: Certain studies have indicated that TCAs might elevate the risk of congenital malformations, potentially associated with defects in their eyes, ears, face, and neck. In addition, TCAs have been linked to preterm delivery, low birth weight, neonatal withdrawal syndrome, and persistent pulmonary hypertension in newborns.<xref ref-type="bibr" rid="article-30600.r28">[28]</xref> Specifically, clomipramine&#x000a0;is associated&#x000a0;with more severe neonatal symptoms, including cardiac defects.<xref ref-type="bibr" rid="article-30600.r29">[29]</xref>&#x000a0;However, other studies have not identified substantial connections between TCAs and adverse pregnancy outcomes.&#x000a0;Overall, TCAs are not typically considered safe medication during pregnancy.&#x000a0;</p>
        <p>If there is a clinical necessity, the decision to use TCAs during pregnancy should be based on carefully evaluating the benefits and risks unique to each case. This should encompass the severity of maternal depression, the response to previous treatments, the potential for drug interactions, and a patient's preferences. Certain TCAs, notably nortriptyline and desipramine, are preferred during pregnancy due to their reduced fetal exposure and more favorable safety profile.</p>
        <p>Breastfeeding considerations: TCAs are excreted into breast milk in varying quantities, depending on their lipophilicity, protein binding, and metabolism. Generally, infants are exposed to low levels of TCAs through breast milk, and there are usually no significant adverse effects. However, a few cases of sedation, irritability, poor feeding, and colic have been reported. TCAs, except doxepin, have not been linked to detrimental effects on breastfeeding, and therefore, they are considered safe for use.<xref ref-type="bibr" rid="article-30600.r30">[30]</xref>&#x000a0;Nortriptyline is considered the safest medication to use during breastfeeding due to its non-sedating profile.<xref ref-type="bibr" rid="article-30600.r29">[29]</xref></p>
        <p>Pediatric patients:&#x000a0;TCAs are generally not approved for use in pediatric patients due to safety concerns and the availability of other better and safer treatment options for this population. The majority of TCAs have not demonstrated superior efficacy compared to placebo for treating depression within pediatric populations. However, clomipramine is an exceptional drug with FDA approval for treating OCD in individuals aged 10 and older.</p>
        <p>Geriatric patients: Caution is advised for older patients using TCA medications due to age-related changes in pharmacokinetics, increased sensitivity to anticholinergic effects, and potential drug interactions. Lower initial doses and a more gradual titration might be necessary for older patients to mitigate the drug's potential risks or adverse effects. Consistent monitoring for cognitive impairment falls and other possible side effects is pivotal within this patient demographic.&#x000a0;Nortriptyline and desipramine may be preferred medications over other TCAs among&#x000a0;older adults due to their reduced anticholinergic effects, diminished cardiac toxicity, and more linear pharmacokinetics.</p>
      </sec>
      <sec id="article-30600.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>TCAs&#x000a0;exhibit diverse receptor affinities that contribute to various adverse effects, including constipation, dizziness, and&#x000a0;xerostomia.<xref ref-type="bibr" rid="article-30600.r31">[31]</xref> As these drugs inhibit cholinergic receptors, their utilization can result in blurred vision, constipation, xerostomia, confusion, urinary retention, and tachycardia in individuals taking the drug.<xref ref-type="bibr" rid="article-30600.r32">[32]</xref> The alpha-1 adrenergic receptor blockade can induce orthostatic hypotension and dizziness.<xref ref-type="bibr" rid="article-30600.r31">[31]</xref><xref ref-type="bibr" rid="article-30600.r32">[32]</xref>&#x000a0;TCA-induced histamine blockade (H1) may lead to sedation, increased appetite, weight gain, and confusion in patients.<xref ref-type="bibr" rid="article-30600.r33">[33]</xref><xref ref-type="bibr" rid="article-30600.r31">[31]</xref></p>
        <p>TCAs may also induce cardiovascular complications, including arrhythmias such as QTc prolongation, ventricular fibrillation, and sudden cardiac death, particularly in individuals with preexisting ischemic heart disease.<xref ref-type="bibr" rid="article-30600.r34">[34]</xref> Therefore, assessing a patient's cardiac health is important before prescribing TCAs. Evidence suggests that TCAs elevate the risk of seizures in individuals with epilepsy, and their usage necessitates caution within this population.<xref ref-type="bibr" rid="article-30600.r35">[35]</xref>&#x000a0;TCAs may cause a minor elevation of liver enzymes; however,&#x000a0;acute hepatitis is seldom associated with&#x000a0;using TCAs.<xref ref-type="bibr" rid="article-30600.r33">[33]</xref><xref ref-type="bibr" rid="article-30600.r36">[36]</xref></p>
        <p>TCA use has been demonstrated to heighten the risk of suicidal ideation and behavior, particularly in individuals aged 24 or younger. Individuals who start taking TCAs at age 24 or younger should be closely monitored for any suicidal thoughts and behaviors.<xref ref-type="bibr" rid="article-30600.r36">[36]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>TCAs have the potential to interact with various medications, thereby leading to clinically significant drug-drug interactions. These interactions can affect TCA plasma levels and therapeutic response, increasing the risk of adverse effects. Healthcare professionals must remain vigilant about potential interactions when prescribing TCAs concurrently with other medications.&#x000a0;</p>
        <table-wrap id="article-30600.table3" position="float" orientation="portrait">
          <caption>
            <title>Table 4. TCA Drug-Drug Interactions and Adverse Effects</title>
          </caption>
          <table style="width: 966px; height: 744px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 26px;">
                <td style="width: 177.006px; height: 26px;" rowspan="1" colspan="1">
<bold>TCA- Drug Interaction</bold>
</td>
                <td style="width: 700.994px; height: 26px;" rowspan="1" colspan="1">
<bold>Potential Effects</bold>
</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 177.006px; height: 26px;" rowspan="1" colspan="1">Monoamine oxidase inhibitors (MAOIs)</td>
                <td style="width: 700.994px; height: 26px;" rowspan="1" colspan="1">Concurrent use of MAOIs with TCAs may cause serotonin syndrome or hypertensive crisis, a life-threatening condition caused by excessive levels of serotonin or norepinephrine in the body.</td>
              </tr>
              <tr style="height: 39px;">
                <td style="width: 177.006px; height: 39px;" rowspan="1" colspan="1">Selective serotonin reuptake inhibitors (SSRIs)</td>
                <td style="width: 700.994px; height: 39px;" rowspan="1" colspan="1">Concurrent use of SSRIs with TCAs may lead to serotonin syndrome or elevated TCA levels in the body due to the inhibitory effect of certain SSRIs on the CYP2D6 enzyme.</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 177.006px; height: 13px;" rowspan="1" colspan="1">Serotonin-norepinephrine reuptake inhibitors (SNRIs)</td>
                <td style="width: 700.994px; height: 13px;" rowspan="1" colspan="1">Concurrent use of SNRIs with TCAs can result in serotonin syndrome or elevated TCA levels in the body due to the inhibitory effect of certain SNRIs on the CYP2D6 enzyme.</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 177.006px; height: 13px;" rowspan="1" colspan="1">Anticholinergic drugs</td>
                <td style="width: 700.994px; height: 13px;" rowspan="1" colspan="1">Concurrent use of anticholinergic drugs, such as antihistamines, antipsychotics, or anti-Parkinsonian drugs, with TCAs may cause additive anticholinergic effects, including dry mouth, constipation, urinary retention, blurred vision, confusion, or delirium.</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 177.006px; height: 13px;" rowspan="1" colspan="1">Anticoagulants</td>
                <td style="width: 700.994px; height: 13px;" rowspan="1" colspan="1">Concurrent use of anticoagulants, such as warfarin or heparin, with TCAs could potentially heighten the risk of bleeding. This might result from either the inhibition of platelet aggregation by certain TCAs or the displacement of warfarin from plasma proteins by specific TCAs.</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 177.006px; height: 13px;" rowspan="1" colspan="1">Lithium</td>
                <td style="width: 700.994px; height: 13px;" rowspan="1" colspan="1">Concurrent use of lithium with TCAs can lead to neurotoxicity, serotonin syndrome, or neuroleptic malignant syndrome. These severe conditions are marked by altered mental status, muscle rigidity, fever, and autonomic instability.</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 177.006px; height: 13px;" rowspan="1" colspan="1">Clonidine</td>
                <td style="width: 700.994px; height: 13px;" rowspan="1" colspan="1">TCAs could potentially diminish the antihypertensive effects of clonidine, as they obstruct the presynaptic alpha-2 receptors that regulate the feedback inhibition of norepinephrine release.</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 177.006px; height: 13px;" rowspan="1" colspan="1">Blood pressure medications</td>
                <td style="width: 700.994px; height: 13px;" rowspan="1" colspan="1">TCAs can interact with blood pressure medications, such as beta-blockers, calcium channel blockers, or clonidine, causing additive or antagonistic effects on blood pressure or heart rate.</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 177.006px; height: 13px;" rowspan="1" colspan="1">Cimetidine</td>
                <td style="width: 700.994px; height: 13px;" rowspan="1" colspan="1">Cimetidine can elevate the levels of TCAs in the body and increase the likelihood of adverse effects.</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-30600.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>TCAs are contraindicated within certain populations and when used concurrently with specific medications. TCAs should not be prescribed to individuals with a family history of QTc interval prolongation or sudden cardiac death. Hypersensitivity reactions to a TCA drug are considered an absolute contraindication. Patients who have a hypersensitivity reaction to a TCA drug can be prescribed a different medication within the same class with caution. TCAs should not be administered concurrently with monoamine oxidase inhibitors (MAOIs), such as phenelzine, due to the risk of developing serotonin syndrome.<xref ref-type="bibr" rid="article-30600.r37">[37]</xref>&#x000a0;</p>
        <p>Furthermore, patients should abstain from MAOI usage for at least 14 days before initiating TCA therapy. The combination of TCAs and SSRIs is not recommended, as this combination has been demonstrated to escalate plasma concentrations of TCAs and heighten the risk of serotonin syndrome.<xref ref-type="bibr" rid="article-30600.r38">[38]</xref><xref ref-type="bibr" rid="article-30600.r39">[39]</xref></p>
        <p>The utilization of TCAs necessitates caution in individuals with angle-closure glaucoma, as the drug's anticholinergic effects could potentially heighten the risk of an acute ocular crisis.<xref ref-type="bibr" rid="article-30600.r40">[40]</xref> TCAs should be used cautiously in patients with a history of seizures, as they might lower the seizure threshold. In addition, caution is warranted in patients with urinary retention, as TCAs' anticholinergic properties could exacerbate this symptom.<xref ref-type="bibr" rid="article-30600.r32">[32]</xref><xref ref-type="bibr" rid="article-30600.r35">[35]</xref>&#x000a0;Although&#x000a0;coronary artery disease (CAD) is not an absolute contraindication for TCAs, clinicians should typically exercise caution when considering this medication for patients with CAD.<xref ref-type="bibr" rid="article-30600.r41">[41]</xref>&#x000a0;</p>
        <p>Due to the metabolism of TCAs by cytochrome P450 enzymes in the liver, caution is necessary when prescribing these medications to patients with hepatic impairment. Clomipramine has demonstrated the highest incidence of drug-induced liver injury, particularly within the TCA class of drugs. As a result, this drug is not the preferred choice for patients with suboptimal liver function.<xref ref-type="bibr" rid="article-30600.r42">[42]</xref></p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>The FDA mandates that all TCAs include a boxed warning on the label, cautioning users about the potential risks and elevation of suicidal thoughts or behaviors when using these drugs. This risk is particularly pronounced in children, adolescents, and young adults between the ages of 18&#x000a0;and 24.</p>
        <p>
<bold>Precautions</bold>
</p>
        <p>TCAs are associated with a higher risk of drug overdose compared to many other classes of antidepressants. In addition, meticulous monitoring of cardiac function, electrocardiogram (ECG), and blood pressure is vital when prescribing TCAs, especially for patients with known cardiac abnormalities.</p>
      </sec>
      <sec id="article-30600.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>TCAs generally exhibit a narrow therapeutic index, and the specific therapeutic range for each TCA depends on&#x000a0;the prescribed drug. Due to the narrow therapeutic index of TCAs, patients should undergo vigilant monitoring for signs of toxicity, such as QRS-widening on ECG, tremors, confusion, muscle rigidity, and coma.<xref ref-type="bibr" rid="article-30600.r23">[23]</xref></p>
        <p>All patients commencing a TCA therapy should undergo screening for preexisting cardiac conditions,&#x000a0;including prolonged QTc intervals, heart disease, and a family history of arrhythmias. Patients who test positive for preexisting heart conditions might necessitate further evaluation by a cardiologist&#x000a0;before initiating TCA treatment. Furthermore, these patients should undergo consistent monitoring for the emergence of new cardiac symptoms. Patients with low potassium blood concentrations should undergo periodic monitoring to mitigate the risk of developing arrhythmias.<xref ref-type="bibr" rid="article-30600.r34">[34]</xref>&#x000a0;Obtaining an ECG for further evaluation is recommended in patients aged 50 and older.</p>
        <p>All patients initiating TCA treatment or currently using TCAs as medications should be monitored for the aggravation of depressive symptoms or the emergence of new-onset suicidal thoughts or behaviors. Monitoring the&#x000a0;blood TCA levels could benefit non-adherent patients with reduced tolerability or minimal drug response. However, mixed evidence exists on the effectiveness of blood concentration monitoring on clinical outcomes.<xref ref-type="bibr" rid="article-30600.r7">[7]</xref></p>
      </sec>
      <sec id="article-30600.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Due to their narrow therapeutic index, TCAs are prone to induce toxicity in the event of accidental or intentional overdose. These drugs have&#x000a0;exhibited higher rates of death per 1 million prescriptions&#x000a0;than other antidepressants, primarily attributed to elevated rates of suicide resulting from deliberate overdose.<xref ref-type="bibr" rid="article-30600.r43">[43]</xref>&#x000a0;</p>
        <p>
<bold>Signs and Symptoms of TCA Overdose</bold>
</p>
        <p>Signs and symptoms of TCA overdose include ECG abnormalities such as QTc prolongation and widened QRS complex, hypotension, seizures, tremors, coma, xerostomia, urinary retention, and respiratory depression.<xref ref-type="bibr" rid="article-30600.r44">[44]</xref> TCAs' most frequent causes of death are generally attributed to hypotension or arrhythmias.<xref ref-type="bibr" rid="article-30600.r45">[45]</xref>&#x000a0;</p>
        <p>
<bold>Management of TCA Overdose</bold>
</p>
        <p>Management of TCA overdose necessitates stabilizing the patient and promptly addressing their acute complications, as listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Activated charcoal may be administered to patients for TCA overdose to prevent drug absorption; however, its use must occur within 2 hours of TCA ingestion.<xref ref-type="bibr" rid="article-30600.r46">[46]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients with a prolonged QRS interval should be administered sodium bicarbonate to elevate their serum pH levels and diminish the concentration of active free TCA medication.<xref ref-type="bibr" rid="article-30600.r47">[47]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Lidocaine could be considered a potential reversal agent in TCA-induced cardiotoxicity resistant to sodium bicarbonate.<xref ref-type="bibr" rid="article-30600.r45">[45]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients experiencing TCA-induced seizures should be provided with benzodiazepines for treatment.<xref ref-type="bibr" rid="article-30600.r48">[48]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients who manifest hypotension should receive IV crystalloids, whereas those demonstrating signs of respiratory compromise should be administered respiratory support.</p>
          </list-item>
          <list-item>
            <p>Patients with hypotension unresponsive to crystalloids should be considered for a trial of norepinephrine.<xref ref-type="bibr" rid="article-30600.r49">[49]</xref></p>
          </list-item>
        </list>
        <p>Given the risk of serotonin syndrome, the concurrent use of TCAs and MAOIs should be avoided.<xref ref-type="bibr" rid="article-30600.r37">[37]</xref>&#x000a0;Patients with serotonin syndrome present with dilated pupils, hyperreflexia, myoclonus, diarrhea, tremors, and confusion. The treatment approaches for serotonin syndrome encompass cooling, discontinuation of serotonergic drugs, and the use of cyproheptadine.</p>
      </sec>
      <sec id="article-30600.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Nowadays, TCAs are frequently prescribed for off-label uses.&#x000a0;Although physicians may prescribe TCAs to treat MDD, they are rarely recommended as a first-line treatment due to their adverse effect profile, encompassing anticholinergic, antihistamine, and antiadrenergic effects. Moreover, numerous safer alternatives, such as SSRIs, are accessible. Nevertheless, physicians might still prescribe TCAs in cases of MDD where conventional antidepressant pharmacotherapy has proven ineffective. Regardless of the indications for TCAs, patients who require treatment with TCAs need the involvement of an interprofessional team to help maintain patient safety.</p>
        <p>If cardiac function abnormalities are present, collaboration among a patient's primary care physician or advanced practice practitioner, psychiatrist, and cardiologist is crucial for maintaining the patient's stability and averting adverse outcomes. Patient monitoring for signs of suicidal intent is necessary to prevent instances of toxicity and overdose.<xref ref-type="bibr" rid="article-30600.r50">[50]</xref> Maintaining communication between&#x000a0;the&#x000a0;patient's cardiologist and prescriber is vital to preempt cardiotoxic outcomes in patients with predisposing risk factors for cardiac dysfunction.<xref ref-type="bibr" rid="article-30600.r34">[34]</xref></p>
        <p>Pharmacists are critical in taking care of patients who are prescribed TCAs. Pharmacists can verify the correct dosage and identify significant drug-drug interactions. Furthermore, as TCAs predominantly undergo liver metabolism, pharmacists can mitigate the risk of interactions with other drugs by identifying concomitant medications that impact hepatic metabolism.<xref ref-type="bibr" rid="article-30600.r51">[51]</xref> Nursing staff can contribute to the process by evaluating patient adherence and overseeing the monitoring of adverse effects. Frequent and open communication among all interprofessional healthcare team members is crucial to provide optimal patient care while minimizing adverse events associated with TCAs.</p>
      </sec>
      <sec id="article-30600.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30600&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30600">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30600/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30600">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30600.s11">
        <title>References</title>
        <ref id="article-30600.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dopheide</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Recognizing and treating depression in children and adolescents.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2006</year>
            <month>Feb</month>
            <day>01</day>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>233</fpage>
            <page-range>233-43</page-range>
            <pub-id pub-id-type="pmid">16434782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stokes</surname>
                <given-names>PRA</given-names>
              </name>
              <name>
                <surname>Jokinen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Amawi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Husain</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Yatham</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Strang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological Treatment of Mood Disorders and Comorbid Addictions: A Systematic Review and Meta-Analysis: Traitement Pharmacologique des Troubles de L'humeur et des D&#x000e9;pendances Comorbides: Une Revue Syst&#x000e9;matique et une M&#x000e9;ta-Analyse.</article-title>
            <source>Can J Psychiatry</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>65</volume>
            <issue>11</issue>
            <fpage>749</fpage>
            <page-range>749-769</page-range>
            <pub-id pub-id-type="pmid">32302221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <chapter-title>Antidepressant Agents</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>4</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">31643899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boafo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Greenham</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bazaid</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suntharalingam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Silbernagel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Magner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Robillard</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Medications for sleep disturbance in children and adolescents with depression: a survey of Canadian child and adolescent psychiatrists.</article-title>
            <source>Child Adolesc Psychiatry Ment Health</source>
            <year>2020</year>
            <volume>14</volume>
            <fpage>10</fpage>
            <pub-id pub-id-type="pmid">32175006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Del Casale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sorice</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Padovano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simmaco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferracuti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lamis</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Rapinesi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Girardi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kotzalidis</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Pompili</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).</article-title>
            <source>Curr Neuropharmacol</source>
            <year>2019</year>
            <volume>17</volume>
            <issue>8</issue>
            <fpage>710</fpage>
            <page-range>710-736</page-range>
            <pub-id pub-id-type="pmid">30101713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.</article-title>
            <source>J Affect Disord</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-36</page-range>
            <pub-id pub-id-type="pmid">10760555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thorstrand</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical features in poisonings by tricyclic antidepressants with special reference to the ECG.</article-title>
            <source>Acta Med Scand</source>
            <year>1976</year>
            <volume>199</volume>
            <issue>5</issue>
            <fpage>337</fpage>
            <page-range>337-44</page-range>
            <pub-id pub-id-type="pmid">5853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Wolff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x000f6;lzel</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Westphal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x000e4;rter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kriston</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis.</article-title>
            <source>J Affect Disord</source>
            <year>2013</year>
            <month>Jan</month>
            <day>10</day>
            <volume>144</volume>
            <issue>1-2</issue>
            <fpage>7</fpage>
            <page-range>7-15</page-range>
            <pub-id pub-id-type="pmid">22963896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>XM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>MX</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>YD</given-names>
              </name>
            </person-group>
            <article-title>Tricyclic antidepressants for preventing migraine in adults.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>96</volume>
            <issue>22</issue>
            <fpage>e6989</fpage>
            <pub-id pub-id-type="pmid">28562550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <article-title>Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group.</article-title>
            <source>Arch Gen Psychiatry</source>
            <year>1991</year>
            <month>Aug</month>
            <volume>48</volume>
            <issue>8</issue>
            <fpage>730</fpage>
            <page-range>730-8</page-range>
            <pub-id pub-id-type="pmid">1883256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Max</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Muir</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shoaf</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Smoller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dubner</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.</article-title>
            <source>N Engl J Med</source>
            <year>1992</year>
            <month>May</month>
            <day>07</day>
            <volume>326</volume>
            <issue>19</issue>
            <fpage>1250</fpage>
            <page-range>1250-6</page-range>
            <pub-id pub-id-type="pmid">1560801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayashida</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Obata</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Strategies to Treat Chronic Pain and Strengthen Impaired Descending Noradrenergic Inhibitory System.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Feb</month>
            <day>14</day>
            <volume>20</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">30769838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pilowsky</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hallett</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Bassett</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Penhall</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>A controlled study of amitriptyline in the treatment of chronic pain.</article-title>
            <source>Pain</source>
            <year>1982</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>169</fpage>
            <page-range>169-179</page-range>
            <pub-id pub-id-type="pmid">6757842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pal</surname>
                <given-names>US</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Trends in management of myofacial pain.</article-title>
            <source>Natl J Maxillofac Surg</source>
            <year>2014</year>
            <season>Jul-Dec</season>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>109</fpage>
            <page-range>109-16</page-range>
            <pub-id pub-id-type="pmid">25937719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dukes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Edelsberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stacey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Oster</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy.</article-title>
            <source>Clin J Pain</source>
            <year>2007</year>
            <season>Mar-Apr</season>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>251</fpage>
            <page-range>251-8</page-range>
            <pub-id pub-id-type="pmid">17314585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radley</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Finkelstein</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Off-label prescribing among office-based physicians.</article-title>
            <source>Arch Intern Med</source>
            <year>2006</year>
            <month>May</month>
            <day>08</day>
            <volume>166</volume>
            <issue>9</issue>
            <fpage>1021</fpage>
            <page-range>1021-6</page-range>
            <pub-id pub-id-type="pmid">16682577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Punay</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Couch</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Antidepressants in the treatment of migraine headache.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-4</page-range>
            <pub-id pub-id-type="pmid">12525271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calandre</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Rico-Villademoros</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Slim</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>An update on pharmacotherapy for the treatment of fibromyalgia.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>1347</fpage>
            <page-range>1347-68</page-range>
            <pub-id pub-id-type="pmid">26001183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000e4;user</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bernardy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>U&#x000e7;eyler</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sommer</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis.</article-title>
            <source>JAMA</source>
            <year>2009</year>
            <month>Jan</month>
            <day>14</day>
            <volume>301</volume>
            <issue>2</issue>
            <fpage>198</fpage>
            <page-range>198-209</page-range>
            <pub-id pub-id-type="pmid">19141768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gepertz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nev&#x000e9;us</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Imipramine for therapy resistant enuresis: a retrospective evaluation.</article-title>
            <source>J Urol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>171</volume>
            <issue>6 Pt 2</issue>
            <fpage>2607</fpage>
            <page-range>2607-10; discussion 2609-10</page-range>
            <pub-id pub-id-type="pmid">15118430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hillhouse</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>A brief history of the development of antidepressant drugs: from monoamines to glutamate.</article-title>
            <source>Exp Clin Psychopharmacol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-21</page-range>
            <pub-id pub-id-type="pmid">25643025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richelson</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Antimuscarinic and other receptor-blocking properties of antidepressants.</article-title>
            <source>Mayo Clin Proc</source>
            <year>1983</year>
            <month>Jan</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-6</page-range>
            <pub-id pub-id-type="pmid">6130192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillman</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.</article-title>
            <source>Br J Pharmacol</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>151</volume>
            <issue>6</issue>
            <fpage>737</fpage>
            <page-range>737-48</page-range>
            <pub-id pub-id-type="pmid">17471183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hiemke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baumann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bergemann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Conca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dietmaier</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Egberts</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fric</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gerlach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Greiner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nder</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Haen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Havemann-Reinecke</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Jaquenoud Sirot</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kirchherr</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Laux</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lutz</surname>
                <given-names>UC</given-names>
              </name>
              <name>
                <surname>Messer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Pfuhlmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rambeck</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Riederer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schoppek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stingl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Uhr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ulrich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Waschgler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zernig</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.</article-title>
            <source>Pharmacopsychiatry</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>195</fpage>
            <page-range>195-235</page-range>
            <pub-id pub-id-type="pmid">21969060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pallanti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hollander</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bienstock</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koran</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leckman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marazziti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zohar</surname>
                <given-names>J</given-names>
              </name>
              <collab>International Treatment Refractory OCD Consortium</collab>
            </person-group>
            <article-title>Treatment non-response in OCD: methodological issues and operational definitions.</article-title>
            <source>Int J Neuropsychopharmacol</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-91</page-range>
            <pub-id pub-id-type="pmid">12135542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sandig</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Campmany</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Campos</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Villena</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Naveros</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Transdermal delivery of imipramine and doxepin from newly oil-in-water nanoemulsions for an analgesic and anti-allodynic activity: development, characterization and in vivo evaluation.</article-title>
            <source>Colloids Surf B Biointerfaces</source>
            <year>2013</year>
            <month>Mar</month>
            <day>01</day>
            <volume>103</volume>
            <fpage>558</fpage>
            <page-range>558-65</page-range>
            <pub-id pub-id-type="pmid">23261580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baethge</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heinz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Langlitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review.</article-title>
            <source>Eur Arch Psychiatry Clin Neurosci</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>255</volume>
            <issue>6</issue>
            <fpage>387</fpage>
            <page-range>387-400</page-range>
            <pub-id pub-id-type="pmid">15868067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000e9;rard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Sheehy</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort.</article-title>
            <source>BMJ Open</source>
            <year>2017</year>
            <month>Jan</month>
            <day>12</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>e013372</fpage>
            <pub-id pub-id-type="pmid">28082367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gentile</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tricyclic antidepressants in pregnancy and puerperium.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>207</fpage>
            <page-range>207-25</page-range>
            <pub-id pub-id-type="pmid">24383525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanza di Scalea</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wisner</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Antidepressant medication use during breastfeeding.</article-title>
            <source>Clin Obstet Gynecol</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>52</volume>
            <issue>3</issue>
            <fpage>483</fpage>
            <page-range>483-97</page-range>
            <pub-id pub-id-type="pmid">19661763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trindade</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Topfer</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Coloma</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis.</article-title>
            <source>CMAJ</source>
            <year>1998</year>
            <month>Nov</month>
            <day>17</day>
            <volume>159</volume>
            <issue>10</issue>
            <fpage>1245</fpage>
            <page-range>1245-52</page-range>
            <pub-id pub-id-type="pmid">9861221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000fc;loglu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Orak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ust&#x000fc;ndag</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Altunci</surname>
                <given-names>YA</given-names>
              </name>
            </person-group>
            <article-title>Analysis of amitriptyline overdose in emergency medicine.</article-title>
            <source>Emerg Med J</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>296</fpage>
            <page-range>296-9</page-range>
            <pub-id pub-id-type="pmid">20923818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>David</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Gourion</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>[Antidepressant and tolerance: Determinants and management of major side effects].</article-title>
            <source>Encephale</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>553</fpage>
            <page-range>553-561</page-range>
            <pub-id pub-id-type="pmid">27423475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fanoe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kristensen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fink-Jensen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Toft</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Videbech</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pehrson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bundgaard</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management.</article-title>
            <source>Eur Heart J</source>
            <year>2014</year>
            <month>May</month>
            <day>21</day>
            <volume>35</volume>
            <issue>20</issue>
            <fpage>1306</fpage>
            <page-range>1306-15</page-range>
            <pub-id pub-id-type="pmid">24644307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johannessen Landmark</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Henning</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Johannessen</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>Proconvulsant effects of antidepressants - What is the current evidence?</article-title>
            <source>Epilepsy Behav</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>61</volume>
            <fpage>287</fpage>
            <page-range>287-291</page-range>
            <pub-id pub-id-type="pmid">26926001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <article-title>Drug interactions with selective serotonin reuptake inhibitors, especially with other psychotropics.</article-title>
            <source>Prescrire Int</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>51</issue>
            <fpage>25</fpage>
            <page-range>25-31</page-range>
            <pub-id pub-id-type="pmid">11503857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schipper</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vanmolkot</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Peeters</surname>
                <given-names>FP</given-names>
              </name>
            </person-group>
            <article-title>[Combining a classic monoamine oxidase inhibitor with a tricyclic antidepressant in therapy-resistant depression: a case report and literature review].</article-title>
            <source>Tijdschr Psychiatr</source>
            <year>2016</year>
            <volume>58</volume>
            <issue>12</issue>
            <fpage>886</fpage>
            <page-range>886-890</page-range>
            <pub-id pub-id-type="pmid">27976787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dunner</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Combining antidepressants.</article-title>
            <source>Shanghai Arch Psychiatry</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>363</fpage>
            <page-range>363-4</page-range>
            <pub-id pub-id-type="pmid">25642112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses.</article-title>
            <source>Br J Psychiatry</source>
            <year>1995</year>
            <month>Nov</month>
            <volume>167</volume>
            <issue>5</issue>
            <fpage>575</fpage>
            <page-range>575-80</page-range>
            <pub-id pub-id-type="pmid">8564311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lieberman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stoudemire</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Use of tricyclic antidepressants in patients with glaucoma. Assessment and appropriate precautions.</article-title>
            <source>Psychosomatics</source>
            <year>1987</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>145</fpage>
            <page-range>145-8</page-range>
            <pub-id pub-id-type="pmid">3432532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alderman</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents.</article-title>
            <source>Am J Med</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>108</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-8</page-range>
            <pub-id pub-id-type="pmid">11059434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedrich</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Akimova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Huf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Konstantinidis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Papageorgiou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Winkler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Toto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Greil</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Grohmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Drug-Induced Liver Injury during Antidepressant Treatment: Results of AMSP, a Drug Surveillance Program.</article-title>
            <source>Int J Neuropsychopharmacol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">26721950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henry</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>A fatal toxicity index for antidepressant poisoning.</article-title>
            <source>Acta Psychiatr Scand Suppl</source>
            <year>1989</year>
            <volume>354</volume>
            <fpage>37</fpage>
            <page-range>37-45</page-range>
            <pub-id pub-id-type="pmid">2589102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Starkey</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Lawson</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Poisoning with tricyclic and related antidepressants--a ten-year review.</article-title>
            <source>Q J Med</source>
            <year>1980</year>
            <season>Winter</season>
            <volume>49</volume>
            <issue>193</issue>
            <fpage>33</fpage>
            <page-range>33-49</page-range>
            <pub-id pub-id-type="pmid">6776584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pentel</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Benowitz</surname>
                <given-names>NL</given-names>
              </name>
            </person-group>
            <article-title>Tricyclic antidepressant poisoning. Management of arrhythmias.</article-title>
            <source>Med Toxicol</source>
            <year>1986</year>
            <season>Mar-Apr</season>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>101</fpage>
            <page-range>101-21</page-range>
            <pub-id pub-id-type="pmid">3784839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hult&#x000e9;n</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Askenasi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dallos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dawling</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Heath</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Volans</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Activated charcoal in tricyclic antidepressant poisoning.</article-title>
            <source>Hum Toxicol</source>
            <year>1988</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>307</fpage>
            <page-range>307-10</page-range>
            <pub-id pub-id-type="pmid">3410479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramasubbu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Scurr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sandilands</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Serum alkalinisation is the cornerstone of treatment for amitriptyline poisoning.</article-title>
            <source>BMJ Case Rep</source>
            <year>2016</year>
            <month>Apr</month>
            <day>11</day>
            <volume>2016</volume>
            <fpage>10.1136/bcr</fpage>
            <page-range>10.1136/bcr-2016-214685</page-range>
            <pub-id pub-id-type="pmid">27068728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woolf</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Erdman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Caravati</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Cobaugh</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Booze</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Wax</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Manoguerra</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Scharman</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Chyka</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Christianson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Troutman</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2007</year>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>203</fpage>
            <page-range>203-33</page-range>
            <pub-id pub-id-type="pmid">17453872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tran</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Panacek</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Foulke</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Response to dopamine vs norepinephrine in tricyclic antidepressant-induced hypotension.</article-title>
            <source>Acad Emerg Med</source>
            <year>1997</year>
            <month>Sep</month>
            <volume>4</volume>
            <issue>9</issue>
            <fpage>864</fpage>
            <page-range>864-8</page-range>
            <pub-id pub-id-type="pmid">9305427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerr</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>McGuffie</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Wilkie</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tricyclic antidepressant overdose: a review.</article-title>
            <source>Emerg Med J</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>236</fpage>
            <page-range>236-41</page-range>
            <pub-id pub-id-type="pmid">11435353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30600.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rudorfer</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Potter</surname>
                <given-names>WZ</given-names>
              </name>
            </person-group>
            <article-title>Metabolism of tricyclic antidepressants.</article-title>
            <source>Cell Mol Neurobiol</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>373</fpage>
            <page-range>373-409</page-range>
            <pub-id pub-id-type="pmid">10319193</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
